Zerlasiran and muvalaplin studies published
December 31, 2024
Results of Phase 2 studies of zerlasiran and muvalaplin in patients with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD) have been published.
More evidence of intraindividual Lp(a) variability
December 11, 2024
Analysis of placebo-treated patients in the Phase 2 OCEAN(a)-DOSE trial of olpasiran in patients with Lp(a) concentration >150 nmol/L and established atherosclerotic cardiovascular disease (ASCVD) has shown notable intraindividual variability in serial Lp(a) concentration during follow-up.
Is Lp(a) lower with high TG?
November 25, 2024
Patients with severe hypertriglyceridaemia (sHTG) (≥ 10 mmol/L) have lower plasma Lp(a) than those with normal lipid levels, irrespective of the cause of sHTG. This is the finding from a retrospective chart review of patients attending a lipid genetics clinic in Canada.
Should Lp(a) levels be measured more than once?
October 16, 2024
Variations in Lp(a) levels with time, recorded in a third of clinically stable patients attending a lipid clinic in Argentina, suggest that repeat measurements may be needed, especially in those with borderline elevated Lp(a) levels. This was the conclusion of Dr Pablo Corral and colleagues who carried out a retrospective analysis of Lp(a) levels in […]
New insights on Lp(a) testing around the world
October 9, 2024
Recently published results of Lp(a) studies in Japan, Pakistan and Poland are helping to build a more detailed picture of Lp(a) levels worldwide, together with broader insights on testing practices.
Should Lp(a) thresholds for CAD risk stratification be different for women and men?
September 23, 2024
Lp(a) may predict coronary artery disease (CAD) risk at a lower level in women than in men, according to results of a study of 1858 patients (53% female) attending cardiology and internal medicine outpatient clinics at a tertiary university hospital in Turkey.
